Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547533 | 0.82 | MDM2 (0.53) | HSD17B2 | |
| SCHEMBL13547532 | 0.78 | MDM2 (0.40) | SIGMAR1HSD17B2TSHR | |
| SCHEMBL10689152 | 0.70 | LMNA (0.55) | HRH3KMT2AALDH1A1ATM | |
| SCHEMBL1904422 | 0.70 | SIGMAR1 (0.79) | SIGMAR1HSD17B2 | |
| SCHEMBL12491341 | 0.70 | SIGMAR1 (0.79) | SIGMAR1HSD17B2 | |
| SCHEMBL11993135 | 0.69 | SIGMAR1 (0.77) | SIGMAR1HSD17B2 | |
| SCHEMBL23562146 | 0.69 | CHRNB2 (0.45) | BRD4TSHRKMT2AALDH1A1ATM | |
| SCHEMBL1901822 | 0.68 | SIGMAR1 (1.00) | SIGMAR1HSD17B2ALDH1A1 | |
| SCHEMBL1902449 | 0.68 | SIGMAR1 (1.00) | SIGMAR1HSD17B2ALDH1A1 | |
| SCHEMBL12490813 | 0.68 | SIGMAR1 (1.00) | SIGMAR1HSD17B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | SIGMAR1 4502/4885HSD17B2 1646/4885HRH3 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.